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Abstract
C-reactive protein (CRP) is a general marker of systemic inflammation and cardiovascular disease (CVD). The genetic
contribution to differences in CRP levels remains to be explained, especially in non-European populations. Thus, the aim of
this study was to identify genetic loci associated with CRP levels in Korean population. We performed genome-wide
association studies (GWAS) using SNPs from 8,529 Korean individuals (7,626 for stage 1 and 903 for stage 2). We also
performed pathway analysis. We identified a new genetic locus associated with CRP levels upstream of ARG1 gene (top
significant SNP: rs9375813, Pmeta= 2.85610
28), which encodes a key enzyme of the urea cycle counteract the effects of nitric
oxide, in addition to known CRP (rs7553007, Pmeta= 1.72610
216) and HNF1A loci (rs2259816, Pmeta= 2.90610
210). When we
evaluated the associations between the CRP-related SNPs with cardiovascular disease phenotypes, rs9375813 (ARG1)
showed a marginal association with hypertension (P= 0.0440). To identify more variants and pathways, we performed
pathway analysis and identified six candidate pathways comprised of genes related to inflammatory processes and CVDs
(CRP, HNF1A, PCSK6, CD36, and ABCA1). In addition to the previously reported loci (CRP, HNF1A, and IL6) in diverse ethnic
groups, we identified novel variants in the ARG1 locus associated with CRP levels in Korean population and a number of
interesting genes related to inflammatory processes and CVD through pathway analysis.
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Introduction
C-reactive protein (CRP) is an acute phase reactant protein and
a general marker of systemic inflammation that is produced by the
liver. High CRP levels are known to be associated with
cardiovascular disease (CVD) risk factors, including hypertension,
coronary heart disease (CHD), and stroke, in addition to
traditional risk factors such as BMI, smoking, diabetes, and
cholesterol levels [1].
The heritability of CRP levels is estimated to be 25% to 40%,
indicating that genetic variations can affect inter-individual or
inter-ethnic group differences in CRP levels [2]. Indeed, CRP
levels vary significantly among different ethnic groups [3]. For
example, serum CRP levels were reported to be relatively lower in
East Asians compared to Europeans, South Asians, and Aboriginal
peoples in Canada [3]. Several large-scale genome-wide associa-
tion studies (GWAS) to identify genetic links to difference in CRP
levels have been undertaken; however, most of these studies were
performed in European populations [4,5]. In addition to the well-
known variants that correlate with CRP levels in Europeans such
as CRP, HNF1A (hepatic nuclear factor 1-alpha), and APOE
(apolipoprotein E), some recent GWASs have identified new
variants such as IL6 (interleukin-6) in the Japanese population and
TREM2 (triggering receptors expressed by myeloid cells 2) in
African American women [6,7]. Differences in allele frequencies,
linkage disequilibrium (LD), effect size, and biological adaptations
may influence the identification of variants in different ethnic
groups [8].
In spite of the identification of these CRP-associated single-
nucleotide polymorphisms (SNPs) and genetic loci by large-scale
GWASs, the genetic contributions to differences in CRP levels still
need further investigation. Biological pathway-based analyses may
be able to obtain more meaningful information from high-
throughput whole genome data [8]. Pathway analysis can even
suggest candidate variants that might be missed in a classical
GWAS approach [9]. In the present study, we used a combined
approach of GWAS and pathway analysis and attempted to
identify SNPs associated with CRP levels in the Korean
population.
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Materials and Methods
Study subjects for stage 1 and stage 2 GWAS
As for the stage 1 subjects, a total of 7,626 individuals were used
who have been participated in the Korea Association Resource
project (KARE, stage I) [10]. Half of the subjects were recruited
from one urban community (Ansan) and the other half came from
one rural community (Ansung), Gyeonggi province, Korea. As for
the stage 2 subjects, 903 independent samples were obtained from
Yonsei University in Korea, which were genotyped with the same
Affymetrix Genome-Wide Human SNP Array 5.0 platform. The
general characteristics of stage 1 and stage 2 subjects including the
CRP levels are summarized in Table S1 in File S1.
Genotyping and quality control of the study population
for stage 1 GWAS
The discovery subjects were genotyped using the Affymetrix
Genome-Wide Human SNP Array 5.0. Genotypes were called
using the BRLMM algorithm (http://media.affymetrix.com/
support/technical/whitepapers/brlmm_whitepaper.pdf). Quality
control was performed according to the previous studies [10,11].
We adjusted the individual data with discordant sex information
and filtered out those with the higher than 3% genotype failure
rate. We also excluded individuals with the heterozygosity rate
more than 3 standard deviations away from the mean. We applied
SNP imputation to increase the coverage of variants by capturing
additional association signals. Imputed SNP data were obtained
from Cho et al. [10] who generated them using IMPUTE software
[12] based on JPT/CHB data of HapMap as a reference panel.
Based on these imputed SNP genotypes, we used standard quality
control parameters such as SNP call rate .95%, minor allele
frequency (MAF) .5% and Hardy-Weinberg equilibrium P.
0.001. We excluded individuals with a CRP level greater than
10 mg/dL for our linear regression analysis. We also excluded
participants with missing CRP levels and with diabetes according
to the previous study [4]. Population stratification analysis of the
phase 1 (KARE) data was already performed by Cho et al. [10]
using principal component analysis and multidimensional scaling,
in which no population stratification was observed. Through this
quality control process, genotypes of 7,626 individuals for
1,219,546 autosomal SNPs were used for association analysis of
the stage 1 cohorts.
Stage 2 GWAS with the independent samples
To confirm the association of the identified SNPs from the stage
1 data, we analyzed an additional data set of 979 Korean
individuals from Seoul area of South Korea, part of the Korean
Metabolic Syndrome Research Initiative study [13]. We applied
the same filtration process described above and selected 903
individuals whose CRP level and covariate information are
available for subsequent analyses.
Ethics statement
The local Ethics Committee approved this study, and written
informed consent was obtained from all patients.This study was
approved by the Institutional Review Board of the Catholic
University of Korea School of Medicine (CUMC07U047).
Statistical analysis
Linear regression analysis was performed assuming an additive
model to determine the association of variants with CRP levels.
Information on CRP levels and covariates were ascertained from
KARE. CRP concentrations were transformed using the natural
logarithm function to ensure a normal distribution. Linear
regression analysis was performed assuming an additive model.
Among the clinical covariates such as age, sex, body mass index,
smoking, drinking, high-density lipoprotein (HDL) cholesterol,
triglycerides, waist circumference, fasting glucose, average pulse,
systolic blood pressure, diastolic blood pressure, and history of type
2 diabetes applied in the previous studies of CRP [14], we applied
age, sex, body mass index, and average pulse for the regression
analysis which are available in most individuals. We combined the
stage 1 and 2 results by inverse-variance meta-analysis under the
assumption of fixed effects. Statistical analyses were performed
using PLINK [15]. We used Haploview (version 1.4) to create
Manhattan plots and to calculate LD using a default distance
option of 500 kb [16]. SNAP software was used to annotate the
proxy of the top SNP [17]. In SNAP, a regional association plot
was drawn with the following options: 1000 Genomes Pilot 1 SNP
data set, CHB and JPT population panel, r2 threshold of 0.8, and a
distance limit between the query SNP and the proxy SNP of
500 kb. The statistical power of the study was evaluated using
QUANTO version 1.2.4 [18]. In QUANTO, a gene only
hypothesis was applied with continuous outcome from indepen-
dent individuals using a desired type I error rate of 0.05 in 2-tailed
test. The study had 90% power to detect association of a variant
with a MAF=0.02 and an effect size of 0.1 for additive model.
SNP prioritization
SNP prioritization was performed via GWASrap (http://
jjwanglab.org/gwasrap) [19]. This tool generates a re-prioritized
genetic variant list by combining the original statistical value and
variant prioritization score. The 13,345 GWAS SNPs with P,
0.01 were applied as input values.
Pathway and network analysis
We used ICSNPathway software to do pathway analysis and to
identify candidate SNPs from our GWAS [20]. To get more
reliable pathway analysis, we also used GSA-SNP software [21]. In
ICSNPathway software, we chose the following options as follows;
500 kb up and downstream of the gene as a rule of mapping SNPs
to the genes; a threshold of P,1023 for extracting SNPs from
GWAS; HapMap Han Chinese in Beijing (CHB) data was used for
the imputation of HapMap population; 200 kb for distance for
calculating LD. The rest of options were set as default in
ICSNPathway software. As the database of pathways, we chose,
Gene Ontology (GO) database. Pathways with false discovery rate
(FDR) ,0.05 and nominal P,0.05 were considered to be
associated with CRP levels. In GSA-SNP software, based on the
unimputed SNP P-values from GWAS, we applied GSA-SNP with
the default parameters: k-th best SNP as 2, SNP-Gene mapping
with hg 18, padding with 620,000 bases, and gene count range of
above 5 and less than 100. For pathway database, we applied the
same GO database both in ICSNPathway and GSA-SNP. We
applied Fisher Statistics to combine the nominal P values from
ICSNPathway and GSA-SNP Software to identify pathways that
show consistent significance by both methods [22]. To analyze and
visualize the pathways identified in the GWAS, GeneMANIA
software was used [23]. In GeneMANIA, we chose the options as
follows: automatically selected weighting method for network
weighting; twenty genes for the number of results to be displayed.
The rest of options were set as default in the software.
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Results
Genome-wide associations with CRP levels and their
replication
The general characteristics of stage 1 and stage 2 subjects are
summarized in Table S1 in File S1. The stage 1 set consisted of
7,626 unrelated Korean subjects (3,586 men and 4,040 women)
and the stage 2 set consisted of 903 Korean individuals (518 male
and 385 female). The mean ages of the stage 1 and 2 subjects were
52.568.6 and 41.868.6 years, respectively. The mean values of
HDL, triglycerides and fasting glucose levels of phase 1
participants were 44.9610.1, 160.26102.2, and 85.5615.8,
respectively. The GWASs for CRP levels in Korean individuals
were performed with imputed SNPs using HapMap II data. The
overall results of the GWAS analyses with the additive model are
shown as a Manhattan plot (Figure 1) and as a quantile-quantile
plot (Figure S1 in File S1). The genomic control inflation factor
(lGC) was 1.0, indicating no evidence of type 1 error inflation.
Eighteen SNPs in the CRP locus and one SNP in the HNF1A
locus were below the traditional genome-wide significance
criterion (561028) (Figure 1 and Table S2 in File S1). We applied
a less stringent criterion (P,161025) to select SNPs for phase 2
study. Ninety-eight SNPs in eight loci passed the threshold and the
CRP levels were largely correlated with the genotypes of each SNP
(Table S2 in File S1). They included 26 SNPs in the CRP locus
(1q23.2) (top significant SNP: rs7553007, P=7.34610216), 17 in
the HNF1A locus (12q24.31) (top significant SNP rs1169310,
P=4.9561028), 40 in the 6q23.2 locus near ARG1 (arginase 1)
(top significant SNP: rs2608951, P=1.9661027), two in the
SNCAIP locus (5q23.2) (top significant SNP rs1841972,
P=4.8761026), one in the EFNA5 (5q21.3) (SNP rs12517578,
P=6.9861026), five in the TNFRSF11B (8q24.12) (top significant
SNP rs2062375, P=5.2261026), five in the ARHGAP12
(10p11.22) (top significant SNP rs796126, P=1.7661026), and
one in the TNFSF11 locus (13q14.11) (top significant SNP
rs17596685, P=6.6961026).
To validate the association of the 98 SNPs identified by GWAS,
we examined the available 92 SNPs in an independent stage 2 set
of 903 Korean individuals (significance criteria of P,0.05 for stage
2). Among them, SNPs in the CRP, HNF1A, and ARG1 loci were
found to be consistently significant (Table S3 in File S1). However,
none of the SNPs in the chromosome 5, 8, 10 and 13 loci were
significant in the stage 2 set. In a subsequent meta-analysis of the
stage 1 and stage 2 results, all three loci were more strongly
associated with CRP levels than in stage 1 and reached the
traditional genome-wide significance criterion (561028): 19 SNPs
in the CRP locus (1q23.2) (most significant SNP: rs7553007,
Pmeta = 1.72610
216), 17 SNPs in the HNF1A locus (12q24.31)
(most significant SNP: rs2393791, Pmeta = 2.90610
210), and 21
SNPs in the ARG1 locus (6q23.2) (most significant SNP:
rs9375813, Pmeta = 2.85610
28) (Table 1). Details are available in
Table S3 in File S1. The results from stage 1, stage 2, and meta-
analysis together indicate that the three loci (CRP in 1q23.2,
HNF1A in 12q24.31 and ARG1 in 6q23.2) were consistently
significant (Table S2 and S3 in File S1).
Among these three significant loci, the CRP and HNF1A loci are
known to be associated with CRP levels [4,24]; however, the ARG1
locus has not been reported as being associated with CRP levels.
In the ARG1 locus, 22 neighboring SNPs of the rs9375813 cluster
in about a 100 kb upstream region of the ARG1 gene were all in
strong LD with one another (Figure 2). The P-values and the LD
values of the neighboring SNPs are summarized in Table S4 in
File S1. Similarly, neighboring SNPs of rs7553007 in the CRP
locus and those of rs2393791 in the HNF1A locus were well
clustered with strong LD. The regional associations and LD plots
of these loci are shown in Figure S2 in File S1.
Figure 1. Manhattan plot showing GWAS results for serum CRP levels in 7,626 Korean subjects. The blue horizontal line (P,1028)
denotes the general threshold for genome-wide significance. The red horizontal line (P,1025) denotes the threshold for selecting loci for stage 2
test. The arrow heads indicate three significant loci that passed the threshold.
doi:10.1371/journal.pone.0095866.g001
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Replication of previously identified SNPs in GWAS
We observed whether the significant loci previously reported as
relevant to CRP levels in European and Japanese populations,
including CRP, HNF1A, IL6R, GCKR, IL6, and APOE-CI-CII
cluster [4,6–7] were replicated in our study. Six of the nine loci
were found to be replicated in our study (Table 2). Details of all the
SNPs in the nine loci are available in Table S5 in File S1.
SNP prioritization
We performed SNP prioritization analysis to identify SNPs with
mediocre p-values, but with potential for high impact using
GWASrap tool [19]. Most top rank SNPs still remained significant
after SNP prioritization (Table S6 in File S1). However, for three
SNPs, rs2608912, rs2608976, rs2608921, their ranking of signif-
icance levels became highly elevated after SNP prioritization from
87th, 88th and 81th to 16th, 17th and 19th, respectively.
Interestingly, the three SNPs are located about 17,25 kb
upstream of ARG1 gene and in perfect LD among themselves,
and also in moderate LD with rs9375813 (D9=0.671) (Figure S3
in File S1).
Associations of the CRP-associated SNPs with
cardiovascular phenotypes
We conducted logistic regression analysis to evaluate the
associations between CRP-related SNPs with disease phenotypes
such as CHD (n= 65), myocardial infarction (MI; n= 55), and
hypertension (n= 1,115). The SNP in ARG1 (rs9375813) showed a
marginal association with hypertension (P=0.0440). The other
two SNPs in CRP and HNF1A did not show any significant
associations with any of the traits (Table S7 in File S1).
Pathway analysis
In addition to GWAS, we performed a pathway analysis to
identify more variants and pathways that may influence CRP
levels. To minimize the potential bias of any single algorithm, we
chose two pathway analysis algorithms to ensure the validity of the
identified pathways. We used ICSNPathway software to identify
candidate SNPs and mechanisms that contribute to CRP level and
to generate pathway hypotheses. In addition, we reconfirmed the
pathways using GSA-SNP software.
We used unimputed Phase 1 GWAS P values for pathway
analysis and identified four candidate SNPs in six pathways
(nominal P,0.001 and FDR,0.001, Table 3 and Table 4) using
ICSNPathway: rs1205 in CRP, rs2464196 and rs2464195 in
HNFIA, and rs1635498 in EXO1. Among these, SNPs in the CRP
and HNF1A loci were also identified through GWAS, while a SNP
in the EXO1 gene was exclusively identified through pathway
analysis. Among the four variants, three were non-synonymous
variants and one was in the regulatory region (Table 3). Although
these probes were not present in the Affymetrix SNP 5.0 arrays, all
were in strong LD with the SNPs represented in the genotyped
data (r 2 ranged from 0.92 to 1.0).
The six pathways identified by ICSNPathway provided six
hypothetical biological mechanisms, including the adaptive
immune response, leukocyte mediated immunity, photoreceptor
outer segment, cell-surface binding, cholesterol binding, and
bacterial cell surface binding (Table 4). In addition to the top-
ranked four candidate variants in the three genes, other genes such
as TLR4, C9, CD36, ABCG1, and ABCA1, which are known to be
related to inflammatory processes, are also involved in these
pathways. Detailed information about each pathway is available in
Tables S82S13 in File S1. Of the six pathways identified by
ICSNPathway, four overlapped with the pathways defined by
T
a
b
le
1
.
R
e
su
lt
s
o
f
th
e
g
e
n
o
m
e
-w
id
e
as
so
ci
at
io
n
st
u
d
y
o
f
se
ru
m
C
R
P
le
ve
ls
.
S
N
P
*
C
h
r
P
o
si
ti
o
n
{
N
e
a
re
st
g
e
n
e
M
in
o
r
a
ll
e
le
M
A
F
S
ta
g
e
1
(n
=
7
6
2
6
)
S
ta
g
e
2
(n
=
9
0
3
)
M
e
ta
-a
n
a
ly
si
s
(n
=
8
5
2
9
)
Q
I2
b
(S
E
)
P
b
(S
E
)
P
b
P
rs
7
5
5
3
0
0
7
1
1
5
7
9
6
5
1
7
3
C
R
P
C
0
.3
6
9
0
.1
8
2
(0
.0
2
3
)
7
.3
46
1
0
2
1
6
0
.0
9
9
(0
.0
4
2
)
1
.9
36
1
0
2
2
0
.1
6
4
1
.7
26
1
0
2
1
6
0
.0
8
5
6
6
.2
3
rs
2
3
9
3
7
9
1
1
2
1
1
9
9
0
8
3
3
9
H
N
F1
A
G
0
.4
7
9
2
0
.1
1
8
(0
.0
2
2
)
8
.8
96
1
0
2
8
2
0
.1
3
8
(0
.0
4
1
)
8
.2
86
1
0
2
4
2
0
.1
2
2
2
.9
06
1
0
2
1
0
0
.6
6
5
0
rs
9
3
7
5
8
1
3
6
1
3
1
7
9
8
9
4
0
A
R
G
1
A
0
.1
1
5
2
0
.1
7
7
(0
.0
3
4
)
2
.3
06
1
0
2
7
2
0
.1
3
2
(0
.0
6
3
)
3
.7
36
1
0
2
2
2
0
.1
6
7
2
.8
56
1
0
2
8
0
.5
3
8
0
C
h
r,
ch
ro
m
o
so
m
e
;
M
A
F,
m
in
o
r
al
le
le
fr
e
q
u
e
n
cy
;
C
R
P
,
C
-r
e
ac
ti
ve
p
ro
te
in
;
SE
,
st
an
d
ar
d
e
rr
o
r;
b
,
Ef
fe
ct
si
ze
o
f
a
m
in
o
r
al
le
le
o
n
n
at
u
ra
l-
lo
g
-t
ra
n
sf
o
rm
e
d
C
R
P
;
Q
,
p
-v
al
u
e
fo
r
C
o
ch
ra
n
e
’s
Q
st
at
is
ti
c
as
se
ss
in
g
if
co
m
b
in
in
g
st
u
d
ie
s
ar
e
h
o
m
o
g
e
n
e
o
u
s;
I2
,
I-
sq
u
ar
e
d
in
d
e
x
q
u
an
ti
fy
in
g
h
e
te
ro
g
e
n
e
it
y.
*M
o
st
si
g
n
if
ic
an
tl
y
as
so
ci
at
e
d
SN
P
in
e
ac
h
lo
cu
s
b
as
e
d
o
n
th
e
m
e
ta
an
al
ys
is
re
su
lt
s
w
e
re
su
m
m
ar
iz
e
d
.
{ S
N
P
p
o
si
ti
o
n
s
w
e
re
b
as
e
d
o
n
th
e
N
C
B
I
h
u
m
an
g
e
n
o
m
e
b
u
ild
3
6
.3
(h
g
1
8
).
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
5
8
6
6
.t
0
0
1
ARG1 Polymorphisms Associated with CRP Levels
PLOS ONE | www.plosone.org 4 April 2014 | Volume 9 | Issue 4 | e95866
GSA-SNP, suggesting the reliability of our pathway analysis
(Table 4). Details of the GSA-SNP analysis are available in Table
S14 in File S1. When we applied Fisher’s method to combine the
nominal P values of ICSNPathway and GSA-SNP, all four
pathways showed consistent significance (P,0.001) (Table S15 in
File S1).
Network analysis of identified pathways
To analyze and visualize the pathways identified in GWAS,
GeneMANIA network analysis was performed. Several new genes
and gene networks were discovered through the analysis of each
pathway. Details of each pathway are available in Figures S42S7
in File S1.
Discussion
We applied the combined methods of GWAS and pathway
analysis to unravel the genetic polymorphisms associated with
CRP levels in 8,529 Korean individuals. Although GWAS has
become the standard approach for the investigation of associations
between common variants and susceptibility to complex diseases
[25], a certain amount of biologically meaningful markers and
genes can be missed because of the stringent statistical threshold
applied to minimize false-positive findings [9]. Pathway analysis
can complement the GWAS approach in estimating genetic
susceptibility to complex diseases like cardiovascular disease and
type-2 diabetes through evaluating the cumulative effects of
functionally related genes [26]. By combining GWAS and
pathway analysis, we identified both well-known and novel genetic
variants associated with CRP levels.
Through independent two-stage GWAS and meta-analysis,
three loci (CRP in 1q23.2, HNF1A in 12q24.31, and ARG1 in
6q23.2) were found to be consistently significant and satisfied the
traditional genome-wide significance criterion (561028). Other
than these three loci, we also identified variants in the EFNA5,
TNFRSF11B, and C12orf43 loci. Although none were significant in
stage 2 testing nor reached the traditional level of significance in
the meta analysis, they are known to be related to the development
of CHD [27].
The variants that showed the strongest associations were located
in and around the CRP locus. This is consistent with previous
GWASs that indicated a strong association of variants in the CRP
and HNF1A loci with CRP levels in people of European, Asian,
and African American ancestries [4,6,28]. The second most
significant variant in our study was in the HNF1A locus. Recently,
Kong et al. reported the association of a HNF1A polymorphism
Figure 2. Regional plot of the SNPs in the ARG1 locus (up) and the LD relationship among these SNPs (down). Data are shown for the
ARG1 locus around rs9375813. Diamond-shaped dots represent -log10 (P-values) of SNPs, and green diamond in the LD plot indicates the most
significant SNP. The strength of LD relationship (r2) between the most strongly associated SNP and the other SNPs is presented with red color
intensities based on JPT+CHB HapMap data. The light blue curve shows recombination rates drawn based on JPT+CHB HapMap data. Green bars
represent the coding genes in this region.
doi:10.1371/journal.pone.0095866.g002
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(rs2393791) with CRP levels and other phenotypes such as
arthritis, tuberculosis, and c-GTP in Korean individuals [29].
HNF1A binds to the CRP promoter and is involved in the
regulation of CRP [5].
The most notable finding in this study was a significant
association of rs9375813 near the ARG1 gene with CRP levels in
the Korean population. This newly identified variant in the 6q23.2
chromosomal region is located approximately 100 kb upstream of
ARG1 and 150 kb downstream of AKAP7. The LD block, where
rs9375813 is located, extends into ARG1 but not into AKAP7. In
addition, three SNPs located about 17,25 kb upstream of ARG1
gene were also found to be significantly associated with the CRP
level in SNP prioritization analysis and in perfect LD among
themselves, and also in moderate LD with rs9375813. All these
data suggest that ARG1 is related to the CRP level. Arginase is one
of the enzymes of the urea cycle in the liver and is critically
involved in various aspects of inflammation [30]. Although an
association between ARG1 polymorphisms and the level of CRP
has not been reported, associations of ARG1 polymorphism with
CVD and asthma have been reported [31,32]. It is well-known
that arginase counteracts nitric oxide (NO) synthase and interferes
with beneficial NO-mediated effects, including vasodilation,
decreased vascular smooth muscle cell proliferation, decreased
interaction between white blood cells and the vascular endothe-
lium, and decreased platelet aggregation [33]. Regarding the
relationship between arginase and CRP levels, Bekpinar et al.
reported that the level of arginase was inversely correlated with
that of hsCRP [34]. Moreover, ARG1 mRNA levels are reported
to be positively associated with the up-regulation of soluble
intercellular adhesion molecule-1, which is a circulating biomarker
for endothelial dysfunction [35]. Combining the results from
previous reports along with our data presented here, we
hypothesize that ARG1 polymorphisms or pathways might play a
role in CRP level variation and cardiovascular traits.
In this study, ARG1 polymorphisms, including the A allele of
rs9375813, were associated with lower CRP levels. To explore the
possibility of whether these ARG1 polymorphisms may be
associated with a lower risk of CVD, we evaluated the association
of ARG1 SNPs with a history of MI, CHD, and hypertension in the
discovery subjects. In our logistic regression analysis of the top
significant SNPs of CRP, HNF1A, and ARG1 loci with cardiovas-
cular phenotypes, the rs9375813 in ARG1 showed a marginally
significant association with hypertension (P,0.044), however, the
other SNPs did not show any significant associations with any of
the traits. This result is in agreement with a report by Elliott et al.
that found no association of variants in the CRP locus and CVD in
a Mendelian randomization study of more than 28,000 cases and
100,000 controls [24]. However, we cannot exclude the possibility
that an effect may not be detected due to limitations in CRP
measurement itself, including the cross-sectional nature of the
measurement and the limited information available on confound-
ing variables such as medication history or the presence of active
inflammation at the time of blood sampling. Also, taking the
relatively low prevalence of the other phenotypes in our study
samples (55 MI and 65 CHD out of 7,626 subjects) into
consideration, further analysis with more cases may help to
evlauate the association more conclusively between the CRP level-
associated SNPs and cardiovascular diseases. In spite of the
limitations described above, it’s worth noting that our study
population is largely disease free population which has already
been used in large-scale GWASs of similar traits [36,10].
Moreover, we have removed the individuals with diabetes mellitus
who may have increased level of inflammation [37,38] from our
study. The rs9375813 MAF varies widely between ethnicities: 0.09
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in Europeans (HapMap CEPH), 0.20 in Africans (HapMap YRI),
and 0.15 in Asians (HapMap HCB and JPT). Considering that
most of the large-scale GWASs for CRP levels have been
performed in Europeans [4,5], the relatively lower MAF in
European people might be one of the reasons why this locus has
not been identified in earlier studies. Asians and Africans seem to
have relatively higher MAFs than Europeans, but the LD
structures are very different between them (Figure S3 in File S1).
At the present time, it remains unclear whether the association
between rs9375813 and CRP levels is Asian-specific; further
studies in diverse ethnic groups will be required to clarify this issue.
In this study, six of the nine significant loci reported in previous
GWASs on CRP levels in diverse ethnic groups were replicated in
our Korean population study (Table 2). This result suggests that
these SNPs may be universally linked to CRP levels in human
beings. Among the replicated SNP loci, those in the IL6R and IL6
genes showed the same directional effect with ours [4,6] while
those in GCKR and HNF1A presented the opposite directional
effect to ours [4]. Interestingly, the directional effect of rs7553007
in CRP differed between studies: A study with Hispanic American
individuals showed similar direction results as presented here [7],
but other studies with Europeans and West Africans showed the
opposite direction [4,28]. In addition, rs10778213 in the ASCL1
gene, which was identified in American women, was not found in
a Japanese population (P=0.54) nor in this study (P=0.06).
To identify more reliable pathways and minimize false positive
findings, we used two different software packages, ICSNPathway
and GSA-SNP. In both softwares, using a full list of GWAS SNP P-
values is desirable. ICSNPathway selects the best –log P value,
while in GSA-SNP, user has the option of selecting the best or
second best SNP within a gene boundary to be assign to the gene.
ICSNPathway compares the distribution of the member gene
scores of a gene set to all the genes using Kolmogor-Smirnov like
running-sum statistics. Variation of the number of member genes
among gene sets is taken care of by multiplying it to factor m1/m2,
where m1 is the proportion of significant genes defined as genes
mapped with at least one of the top 5% most significant SNPs of
all SNPs in GWAS for pathways and m2 is the proportion of
significant genes for all the genes in the GWAS [20]. On the other
hand, in GSA-SNP, the scores of its member genes are averaged
for each gene set and significance is estimated using Z-statistics of
these scores [22]. FDR is computed for multiple testing
corrections.
Four out of six pathways from ICSNPathway analysis
overlapped with pathways identified by GSA-SNP at the FDR
cut off of ,0.001 (Table 4), indicating reliability of the identified
pathways. When we applied Fisher Statistics to combine the
nominal P values of ICSNPathway and GSA-SNP, all four
pathways showed consistent significance (P,0.001). However, a
number of the pathways were identified only by GSA-SNP which
suggests that there is a possibility of false positives in the pathway
analysis results and cross validation will help to rule out them. The
significantly enriched genes in these pathways, such as CRP,
HNF1A, PCSK6, CD36, and ABCA1, have a link either to
inflammation or CVD. The top significant SNP in this study,
CRP, has also been reported as a top significant gene associated
with CRP levels in almost all GWASs reported so far [4,7]. In
addition to CRP, CD36 is one of the key genes enriched in the cell
surface binding pathway, and has been reported to be associated
with inflammation-mediated diseases such as atherosclerosis [39].
A number of studies have suggested a plausible mechanism that
may link genes enriched in the cholesterol binding pathway to
inflammation or to the etiology of atherosclerosis [40]. Indeed, the
key genes enriched in the cholesterol binding pathway have links
to cholesterol efflux (ABCG1), inflammation, and atherosclerosis
(ABCB1 and APOA2) [41]. These results strongly suggest that the
genes enriched in the cholesterol binding and cell surface binding
pathways are involved in the regulation of inflammation, which is
linked to CRP levels and may be involved in atherosclerosis
pathogenesis. Although the term photoreceptor outer segment has
no biological relevance to CRP or inflammation, the genes
enriched in this pathway have biological relevance to CRP
(HNF1A) [5], high triglycerides (PCDH15) [42] and metabolic
syndrome (GNAT3) [43]. Likewise, the genes enriched in bacterial
cell surface binding pathway have relevance to the CRP level
(CRP), atherosclerosis (CD36) and inflammation (PCSK6) [44–46].
Two pathways identified by ICSNPathway, the adaptive immune
response and leukocyte mediated immunity pathways, did not
overlap with pathways identified by GSA-SNP. Although not
overlapped in both software packages, genes enriched in the two
pathways have a putative connection with inflammation and
CVDs [47,48]. In addition, some pathways identified only by
GSA-SNP have potential implications in the inflammation and
CVD pathways. GSA-SNP identified 116 pathways at the FDR
cutoff of ,0.001 in this study (Table S14 in File S1), with the top-
ranked pathway identified as low-density lipoprotein particle
binding. The top enriched genes in this pathway were CRP,
CDH13, STAB2, THBS1, and SORL1. CDH13 variants have been
reported to be associated with hypertension [49]. It is worth noting
that arginase II was enriched in cellular response to the interferon
gamma pathway in GSA-SNP analysis (Table S12 in File S1).
Although arginase I and arginase II are localized differently, both
isoforms catalyze the hydrolysis of L-arginine to L-ornithine and
urea [50]. This result is additional supporting evidence that ARG1
polymorphism or pathways related with ARG1 might play a role in
CRP level variation and cardiovascular traits.
To analyze and visualize the pathways identified in the GWAS,
GeneMANIA network analysis was performed. This analysis can
help to find new genes that have phenotypic relations with query
gene, which will be useful for selecting the candidates for further
functional study. We also examined whether the enriched genes in
the network analysis were reported as being associated with
immune response or CVD. In the photoreceptor outer segment
pathway, some of the newly identified genes such as RAP1A and
CACNA1C have a connection with inflammation [51,52]. Inter-
estingly, CACNA1C has reported to be enriched in pathway
analysis of inflammatory conditions such as Crohn’s disease
[51,52]. Among the newly identified genes in that pathway,
PDE6H and MYL6B had higher weight in the network (Figure S4
in File S1). Some of the newly identified genes in the cholesterol
binding pathway, SHH, APOF and APOC1, were also associated
with cholesterol transport or CVD [53,54]. Among them, DHH,
SHH and PTCH2 had higher weight in the network (Figure S6 in
File S1). The key members of the cell surface binding and bacterial
cell surface binding networks such as TLR6, CD14, CD244, CD58,
SCARB2, and SCARB1 have interconnected roles in inflammatory
responses and CVD [55,56]. Among them, SCARB1 and SCARB2
had higher weight in the bacterial cell surface binding network
(Figure S7 in File S1). Especially, SCARB1 plays a vital role in
reverse cholesterol transport and is also involved in the removal of
cholesterol [57]. Taken together, through GeneMANIA network
analysis of the identified pathways, we were able to identify more
genes related to inflammation or CVD.
Overall, some CRP-associated polymorphisms enriched in the
pathways are involved in the inflammation or pathogenesis of
CVDs. Although we did not explore the biological effects of
polymorphisms identified through pathway analysis, these genes
and pathways may help to generate hypotheses for further
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functional studies investigating the inter-individual differences in
CRP levels and CVD risk.
Our study has several limitations. First, the nature of serum
CRP as an acute reactant itself can be a limitation. The baseline
CRP level in each individual should be estimated based on
repetitive measurements, preferably in the absence of acute
inflammatory conditions, which we could not achieve in this
study. Second, the sample size of the replication set may not be
large enough to verify the potential associations with CRP levels.
To confirm the associations we identified, replication in a large
meta-analysis of CRP GWAS specifically in Asian population will
be required. After that, meaningful functional studies on the SNP
shoud follow.
In conclusion, by combining GWAS, pathway and gene
network analysis, we identified novel ARG1 variants and a number
of interesting candidate genes related to inflammatory processes
and CVDs such as CRP, HNF1A, PCSK6, CD36, and ABCA1 in the
Korean population. Our results also strongly corroborate the
previously reported loci (CRP, HNF1A, IL6) known to be
associated with CRP levels in diverse ethnic groups. This study
highlights the effectiveness of combining GWAS and pathway
analysis in identifying new genetic variants in meaningful
pathways, which can improve our understanding of the genetic
mechanisms behind variations in CRP levels.
Supporting Information
File S1 Figure S1, A Quantile–Quantile plot of P-values in the
GWAS for serum CRP levels (Stage 1). The horizontal axis
indicates the expected -log10 (P-values). The vertical axis indicates
the observed -log10 (P-values). The red line represents y = x.
Figure S2, (A) Stage 1 data showing a regional association (upper
panel) and linkage disequilibrium (LD; lower panel) plots of the
CRP locus around rs7553007. Arrow head represents rs7553007.
(B) Stage 1 data showing a regional association (upper panel) and
linkage disequilibrium (LD; lower panel) plots of the HNF1A locus
around rs2393791. Arrow head represents rs2393791. Figure S3,
Pairwise linkage disequilibrium (LD) between the selected SNPs in
ARG1 locus around rs9375813. LD plots for Korea population
were drawn using the genotype data from the present study,
whereas LD plots for Japanese, Chinese, Europeans and Africans
were made from genotype data from HapMap Stage 2. Blue ID
indicates the most significant SNP. Purple ID indicates the SNPs
whose rank got elevated after re-prioritization. Figure S4, Gene
network of photoreceptor outer segment pathway by GeneMA-
NIA analysis. Using the genes identified from pathway analysis,
GeneMANIA network analysis was performed. Query genes are
depicted as black nodes and discovered genes are depicted as gray
nodes. Edges show different interactions among genes; purple
indicates for co-expression; light-blue indicates for pathway; dark
yellow indicates for shared protein domains; red indicates for
physical interactions; dark blue indicates for co-localization; green
indicates for genetic interactions. Node sizes are determined
according to their weight in the network. Figure S5, Gene
network of cell surface binding pathway by GeneMANIA. Figure
S6, Gene network of cholesterol binding pathway by GeneMA-
NIA. Figure S7, Gene network of bacterial cell surface binding
pathway by GeneMANIA. Table S1, Characteristics of the
subjects in stage 1 and 2 data. The stage 1 consists of 7,626
unrelated Korean subjects (3,586 men and 4,040 women) and the
stage 2 consists of 903 Korean individuals (518 male and 385
female). Table S2, SNP loci associated with serum CRP levels in
the stage 1 data. Table S3, SNP loci associated with serum CRP
levels in the stage 2 data and meta-analysis. Table S4, P-values
and LD values of neighboring SNPs of the rs9375813 in the ARG1
locus. Table S5, Associations of the previously reported CRP-
related loci. Based on genotyped and imputed SNP data, we
observed the associations of previously reported CRP-associated
loci. Table S6, Re-prioritized genetic variants list after GWAS.
Table S7, Associations of the top significant SNP polymorphisms
on cardiovascular disease traits based on the whole KARE samples
(7,626 samples). Table S8, Genes mapped with variant in
adaptive immune response. We performed a pathway analysis to
identify more variants and pathways that may influence CRP
levels using ICSNPathway software and reconfirmed the identified
pathways with GSA-SNP software. This table shows the genes
mapped with variants in adaptive immune response among the ten
candidate pathways enriched with CRP-associated SNPs in
ICSNPathay analysis. Table S9, Genes mapped with variant in
leukocyte mediated immunity. Table S10, Genes mapped with
variant in photoreceptor outer segment. Table S11, Genes
mapped with variant in cell surface binding. Table S12, Genes
mapped with variant in cholesterol binding. Table S13, Genes
mapped with variant in bacterial cell surface binding. Table S14,
Pathway analysis results of GSA-SNP software. Table S15,
Combined P value estimation of ICSNPathway and GSA-SNP by
Fisher Statistics.
(PDF)
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